Tumor-associated antigen peptide (TAA peptide)

Tumor-associated antigen peptides are short peptides derived from self proteins that are overexpressed, differentiation-restricted, or cancer–testis restricted in tumors and presented on HLA class I molecules on cancer cells and extracellular vesicles; they can elicit CD8+ T-cell responses and are used as targets for cancer immunotherapies, but because many TAAs are also expressed at lower levels in some normal tissues, targeting them carries risks of on-target/off-tumor toxicity and variable immunogenicity.[6][3][2]

Other names

tumor-associated antigenic peptideTAAtumor antigen peptideshared tumor antigen peptidedifferentiation antigen peptideoverexpressed antigen peptidecancer-testis antigen peptide

Vaccine-induced T-cell activation against TAA-derived peptides; CAR-T or TCR-T cell recognition of peptide–HLA complexes; Immune checkpoint blockade that augments T-cell responses to TAA peptides